Catabasis Pharmaceuticals to Present Results from the MoveDMD® Trial of Edasalonexent (CAT-1004) at the 2017 PPMD Annual Con...
June 23 2017 - 8:00AM
Business Wire
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, today announced that it will present
data from Part A and Part B of the MoveDMD trial of edasalonexent
(CAT-1004) in an oral presentation at the upcoming 2017 Parent
Project Muscular Dystrophy (PPMD) Annual Connect Conference to be
held June 29 – July 2, 2017, in Chicago, IL, at the Chicago
Marriott Downtown.
Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Catabasis,
will deliver a presentation titled “MoveDMD: Phase 2 Trial of
Edasalonexent, an NF-kB Inhibitor, in 4 to 7-Year Old Patients with
Duchenne Muscular Dystrophy” on Friday, June 30, 2017, from 4:30pm
– 4:45pm CT.
About Edasalonexent (CAT-1004)Edasalonexent (CAT-1004) is
an investigational oral small molecule that is being developed as a
potential disease-modifying therapy for all patients affected by
DMD, regardless of their underlying mutation. Edasalonexent
inhibits NF-kB, a protein that is activated in DMD and drives
inflammation and fibrosis, muscle degeneration and suppresses
muscle regeneration. We are currently conducting the MoveDMD trial,
a three-part clinical trial investigating the safety and efficacy
of edasalonexent in boys ages 4 – 7 affected with DMD (any
confirmed mutation). The third part of the trial, an open-label
extension with edasalonexent, is ongoing. The FDA has granted
orphan drug, fast track and rare pediatric disease designations and
the European Commission has granted orphan medicinal product
designation to edasalonexent for the treatment of DMD. For a
summary of clinical results reported to-date, please visit
www.catabasis.com.
About CatabasisAt Catabasis Pharmaceuticals, our mission
is to bring hope and life-changing therapies to patients and their
families. Our SMART (Safely Metabolized And Rationally Targeted)
linker drug discovery platform enables us to engineer molecules
that simultaneously modulate multiple targets in a disease. We are
applying our SMART linker platform to build an internal pipeline of
product candidates for rare diseases and plan to pursue
partnerships to develop additional product candidates. For more
information on the Company's drug discovery platform and pipeline
of drug candidates, please visit www.catabasis.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170623005022/en/
Investor and Media ContactCatabasis
Pharmaceuticals, Inc.Andrea Matthews,
617-349-1971amatthews@catabasis.com
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Apr 2023 to Apr 2024